New U.S. Patent Strengthens Adial's Genetic-Based Approach To Alcohol And Opioid Disorder Treatment

Adial Pharmaceuticals, Inc., a clinical-stage biopharma company focused on addiction treatment, has announced the issuance of U.S. patent number 12,274,692 on April 15, 2025. The patent covers a novel method of treating alcohol-related diseases and opioid-related disorders using Adial’s investigational drug, AD04, in genetically identified patients.

“This patent represents yet another significant milestone for Adial Pharmaceuticals as we advance our mission to provide targeted treatments for individuals suffering from alcohol and opioid use disorders,” said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. “By identifying genetic markers associated with AD04 response, we are pioneering a precision medicine approach for AUD that has the potential to enhance treatment efficacy and improve patient outcomes. We remain committed to advancing AD04 through clinical development and regulatory pathways to address the urgent need for effective, personalised addiction treatments.”

The patent enhances Adial’s intellectual property portfolio by securing claims for the precision use of AD04 in patients with specific genetic profiles. It includes the use of AD04 in individuals with serotonin-related gene variants, including particular genotypes of HTR3A, HTR3B, and SLC6A4. Notably, the patent emphasises the LL genotype of 5-HTTLPR in combination with other variations such as rs1150226, rs17614942, and rs1176713, highlighting a personalised medicine approach.

Beyond treating alcohol use disorder (AUD), the patent also claims AD04's potential use in related conditions like alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disorders, gambling disorder, and alcohol withdrawal.